New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday 20 November 2026
Export PCSA’s income statement to Excel — free account
Heatwurx Inc.
PCSA- EPS
- n/m
- Free cash flow
- n/m
Quarter to September 2026, against a year earlier
1.67
0.03
−1.76%
Follow PCSA
Alert me
Heatwurx Inc. (PCSA) news
Headlines
- Processa Pharmaceuticals to Participate in Upcoming Investor Conferences GlobeNewswire
- Processa Pharmaceuticals Announces Corporate and Pipeline Progress Following Acquisition of Vidya Therapeutics GlobeNewswire
- Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
- Processa Pharmaceuticals Acquires Vidya Therapeutics and Secures $200 Million Financing to Advance BTK Inhibitor Pipeline InvestorsHub
- PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREAS
- Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire
- Alliance Entertainment and Processa Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV ACCESS Newswire
- Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study
- Processa Pharmaceuticals and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV ACCESS Newswire
- Top Midday Gainers MT Newswires
- Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer
- Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely? Simply Wall St.
- Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025 GlobeNewswire
- BC-Most Active Stocks Associated Press Finance
- Insider Stock Buyers At Processa Pharmaceuticals Recouped Some Losses This Week
- Processa Pharmaceuticals and BullFrog AI Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV ACCESS Newswire
- Processa Pharmaceuticals, Inc. (PCSA) Secures Buy Rating on Portfolio Progress
- Processa Pharmaceuticals Provides Portfolio and Business Update GlobeNewswire
- Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering GlobeNewswire
- Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate GlobeNewswire
- Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025
- Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting
- Processa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025 GlobeNewswire
- Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference GlobeNewswire
- Processa Pharmaceuticals, Inc. (PCSA): Among the Cheapest Stocks Insiders Are Buying Recently Insider Monkey
- Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference GlobeNewswire
- Favourable Signals For Processa Pharmaceuticals: Numerous Insiders Acquired Stock Simply Wall St.
- Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules GlobeNewswire
- Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules GlobeNewswire
- Processa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results GlobeNewswire